InvestorsHub Logo
Followers 18
Posts 2991
Boards Moderated 0
Alias Born 01/29/2013

Re: None

Wednesday, 06/29/2022 6:45:00 AM

Wednesday, June 29, 2022 6:45:00 AM

Post# of 154
Analysts rating: 1 buy, 2 Holds, no underweights or sell ratings. This was before the FDA approved them for commercial launch of AcQCross Line Extension. This can't do anything but go up once profit takers are out of the way, which may already be about over. Look out above. IMO